Donors have been reluctant to fund cannabis research on an extensive scale. Recent developments, however, suggest this dynamic may soon change—with major upsides for universities.
A group of heavy hitters, now including the Gates Foundation, are backing a research effort to ensure that global health systems aren’t outflanked by antibiotic-resistant bacteria. The stakes could hardly be higher.
HHMI’s Investigator program—already legendary for its flexible, long-term streams of funding—has now outdone itself, bumping up the period that it supports researchers to seven years. What’s behind this move?
Foundations and research groups increasingly see out-of-the-box collaborations as holding the key to faster medical breakthroughs. Which explains why a top brain funder and heart organization are teaming up.
CZI is playing the long game with its health science funding. Its latest boost to the Human Cell Atlas project seeks to create the framework for global cooperative research for decades to come.
Women of color are disproportionately affected by HIV/AIDS and the harsh practices of the criminal justice system. Now, this group is getting new help around these issues from a top funder in California.
Despite a fast-aging population and growing strains on healthcare entitlements, only a limited number of funders are looking at ways our society can better manage how people die. Still, some money is flowing.
The Aileen Getty Foundation has joined two high-profile grantmakers making waves on the HIV/AIDS funding scene in the Southern states. Who’s winning grants from this new collaboration?
The Open Philanthropy Project is now moving $100 million in grants a year, so it's a big deal that its research funding has finally been getting up to speed after a long gestation. Here's a peek.
The NIH's Accelerating Medicines Partnership, which launched in 2014, is bringing together different sectors in new ways. Now, it's teaming up with the Michael J. Fox Foundation on Parkinson's.
The philanthropic arm of a pharmaceutical company branches out from its usual focus on diseases to look at the social determinants of health with a new gift and funding stream.
The Open Philanthropy Project has been feeling out different approaches for its nascent science program. One interesting RFP sent $11 million to a handful of applicants the NIH had to turn away.
While the days of doctors making house calls are long gone, one couple is trying to bring the practice back for Parkinson’s patients, who can end up homebound and unable to get the treatment they need.
While you might think that a lot of major health funders would be focused on diabetes, that's not really the case. On the upside, some of the foundations that are paying attention have very deep pockets.
Critics worry that a $200 million donation for alternative medicine from a tech billionaire and his wife will tar UC Irvine's Medical School as a haven for quacks. But the gift raises larger questions.
The Breast Cancer Research Foundation is a great example of how funding intermediaries keep gaining momentum, wielding new resources and clout, especially when it comes to medical research.
Sickle cell disease affects millions of people worldwide and is the most common inherited blood disorder in the U.S., but few funders prioritize finding a cure. Here's a major exception.
In what's becoming a familiar trend, a gift to Boston University finds a billionaire donor trying to propel his alma mater to the upper echelons of the American university research system with a stroke of a pen.
More than 95 percent of healthcare spending goes to direct medical services, but 70 percent of health outcomes can be tied to social determinants. A group of funders wants to change that dynamic.
Women of color account for 80 percent of new HIV diagnoses. But stigma and isolation can make it uniquely difficult for these women to get treatment. A pharma funder is working the problem.
Philanthropic giving for disease research pales next to what the Feds spend. But funders try to get a lot of bang for the buck by backing young scientists and riskier projects. Hilton's giving on MS is a case in point.
Heavy hitters like Gates and Wellcome Trust are demanding that grantees publicly disclose the results of all clinical trials within 12 months. Till Bruckner of Transparify explains what's at stake.
A breakthrough in gene-altering cancer therapy is a case study of how philanthropy can play a role in advancing important research, in tandem with government and industry.
Pancreatic cancer is one of the toughest cancers out there, as far as funding is concerned. But a push to mobilize new resources has been gaining steam—and financing increasingly interesting grants.
The Microsoft billionaire is giving tens of millions of dollars to support "out-of-the-box approaches at the very edges of knowledge." What does that look like in practice, exactly?
A lot is happening with the Parker Institute for Cancer Immunotherapy that the tech billionaire launched last year. But is this thing living up to all the hype that surrounded its rollout?
Until the intervention of the Helmsley Charitable Trust a decade ago, type 1 diabetes was something of a stepchild in the medical research world. The foundation has helped to change that.
Big gifts are flowing for local cancer treatment facilities that offer care that was once unavailable in places like rural Maine. But there are growing questions about effectiveness.
In an era of uncertain federal commitments, how can philanthropy refocus its energies on what remains a profound global health crisis? We talk to the leaders of Funders Concerned About AIDS.
A growing number of funders are excited about using genomics to design and implement far more precise and effective medical treatments plans, saving lives, and also money. Where are grants going?